Ethylpropyllysergamide

EPLA
Clinical data
Other names	N-Ethyl-N-propyllysergamide; Ethylpropyllysergamide; EPLA; Lysergic acid ethylpropylamide; LEP; LEP-57; N-Ethyl-6-methyl-N-propyl-9,10-didehydroergoline-8β-carboxamide
Drug class	Serotonergic psychedelic; Hallucinogen
Identifiers
	IUPAC name (6aR,9R)-N-ethyl-7-methyl-N-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
PubChem CID	166935919;
Chemical and physical data
Formula	C21H27N3O
Molar mass	337.467 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC;
	InChI InChI=1S/C21H27N3O/c1-4-9-24(5-2)21(25)15-10-17-16-7-6-8-18-20(16)14(12-22-18)11-19(17)23(3)13-15/h6-8,10,12,15,19,22H,4-5,9,11,13H2,1-3H3/t15-,19-/m1/s1; Key:LRVSYILBFXYJOP-DNVCBOLYSA-N;

N-Ethyl-N-propyllysergamide (EPLA), also known as lysergic acid ethylpropylamide (LEP or LEP-57), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the amide group has one ethyl group and one propyl group instead of two ethyl groups.

The drug shows affinity for serotonin receptors and acts as a serotonin 5-HT_2A receptor agonist similarly to LSD. EPLA has about one-third of the potency of LSD in producing psychedelic effects in humans. Its exact dosage has not been reported.

EPLA was first described in the scientific literature by at least 1959. It was reportedly encountered as a designer drug by the 1990s.